Molecular classification and clinical significance of endometrial cancer complicated with adenomyosis

Background/Objectives: To study the molecular classification of endometrial cancer combined with adenomyosis and compare its differences in molecular classification and clinicopathological characteristics with endometriosis adenocarcinoma without simultaneous adenomyosis, in order to evaluate the prognosis. Methods: A total of 131 cases of patients with endometrial cancer who underwent initial surgical treatment at Xuanwu Hospital, Capital Medical University from January 1, 2017 to December 31, 2024 were selected for retrospective analysis, Compare the differences in molecular typing and clinicopathological characteristics between 21 cases of endometrial cancer combined with adenomyosis and 110 cases of endometriosis adenocarcinoma without simultaneous adenomyosis. Results: There was no statistically significant difference in molecular typing between endometrial cancer combined with adenomyosis and endometriosis adenocarcinoma without simultaneous adenomyosis ( P=0.398), There were statistically significant differences in the surgical pathological stage and serum CA125 level between the two groups of patients( P<0.05、P=0.029;P<0.05、P=0.005). There were no statistically significant differences between the two groups of patients in terms of height, age, weight, BMI, menopause, vaginal bleeding, uterine cavity space-occupying lesion, vaginal discharge, number of pregnancies, number of deliveries, family history, combined hypertension or diabetes, endometrial thickness, degree of pathological differentiation, LVSI, lesion size and depth of myometrial invasion. No significant differences in general. Conclusion: EC complicated with adenomyosis is an estrogen-dependent tumor, most of which are adenocarcinoma by histopathology. The molecular subtype of EC complicated with adenomyosis is different with endometriosis adenocarcinoma without simultaneous adenomyosis, but the CA125 level is higher and the local invasion ability of the tumor is stronger.